Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Journal of Clinical Pharmacology
|
November 12, 2013
Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy
Juan Jose Pérez Ruixo, Jenny Zheng, Jaap W Mandema
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 26, 2015
A model-based dose-response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma
Susan Raber, Jaap W Mandema, Hanbin Li, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 11, 2014
Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis
Jaap W Mandema, Jenny Zheng, Cesar Libanati, et al.
Pharmaceutical Research
|
December 10, 2003
The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain
Peter A Lockwood, Jack A Cook, Wayne E Ewy, et al.
The AAPS Journal
|
December 16, 2005
Model-based development of gemcabene, a new lipid-altering agent
Jaap W Mandema, David Hermann, Wenping Wang, et al.
Journal of Clinical Pharmacology
|
October 31, 2015
Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis
Yehong Wang, Rui Zhu, Jim Xiao, et al.
Clinical Pharmacokinetics
|
July 8, 2003
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis
Ulf G Eriksson, Jaap W Mandema, Mats O Karlsson, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 25, 2010
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution
Jeffrey A Pfefferkorn, John Litchfield, Richard Hutchings, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Journal of Clinical Pharmacology
|
November 12, 2013
Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy
Juan Jose Pérez Ruixo, Jenny Zheng, Jaap W Mandema
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 26, 2015
A model-based dose-response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma
Susan Raber, Jaap W Mandema, Hanbin Li, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 11, 2014
Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis
Jaap W Mandema, Jenny Zheng, Cesar Libanati, et al.
Pharmaceutical Research
|
December 10, 2003
The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain
Peter A Lockwood, Jack A Cook, Wayne E Ewy, et al.
The AAPS Journal
|
December 16, 2005
Model-based development of gemcabene, a new lipid-altering agent
Jaap W Mandema, David Hermann, Wenping Wang, et al.
Journal of Clinical Pharmacology
|
October 31, 2015
Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis
Yehong Wang, Rui Zhu, Jim Xiao, et al.
Clinical Pharmacokinetics
|
July 8, 2003
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis
Ulf G Eriksson, Jaap W Mandema, Mats O Karlsson, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 25, 2010
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution
Jeffrey A Pfefferkorn, John Litchfield, Richard Hutchings, et al.
Page
of 1